Burning Rock Biotech (BNR) to Release Quarterly Earnings on Tuesday

Burning Rock Biotech (NASDAQ:BNR) is projected to release its Q4 2025 results before the market opens on Tuesday, March 31st. Analysts expect Burning Rock Biotech to post earnings of ($2.2875) per share and revenue of $19.20 million for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, March 12, 2026 at 7:00 AM ET.

Burning Rock Biotech (NASDAQ:BNR) last released its quarterly earnings results on Saturday, February 14th. The company reported ($0.21) EPS for the quarter. The company had revenue of $18.05 million for the quarter. Burning Rock Biotech had a negative return on equity of 9.98% and a negative net margin of 10.27%.

Burning Rock Biotech Trading Down 11.6%

Shares of NASDAQ:BNR opened at $16.36 on Friday. The company has a 50 day moving average of $27.03 and a 200-day moving average of $19.25. The firm has a market cap of $176.03 million, a P/E ratio of -20.71 and a beta of 1.35. Burning Rock Biotech has a twelve month low of $2.18 and a twelve month high of $41.72.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Burning Rock Biotech in a report on Wednesday, January 21st. Wall Street Zen raised Burning Rock Biotech from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Burning Rock Biotech presently has a consensus rating of “Sell”.

Institutional Investors Weigh In On Burning Rock Biotech

An institutional investor recently bought a new position in Burning Rock Biotech stock. Marshall Wace LLP acquired a new stake in shares of Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 10,903 shares of the company’s stock, valued at approximately $220,000. Marshall Wace LLP owned about 0.10% of Burning Rock Biotech as of its most recent filing with the Securities and Exchange Commission. 30.03% of the stock is currently owned by hedge funds and other institutional investors.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.